David D., 6

David is a 6 year old male child living with his parents. He is the third child of his family. He is is a pupil of a government primary school. The parents are struggling to take care of the children in the family. Father is a small-scale farmer and mother is a cleaner. They have a 2 rooms apartment, a pit toilet, a well, and have access to electricity. Monthly family income is 15000. David is 6 years old Sickler who presented with severe bilateral thigh pains of 24 hours. There is history of passage of concentrated urine and fever prior to onset of the pains. Pain has been severe enough to prevent him from sleeping. There is history exposure to mosquito bite as well. No abdominal distension but there is abdominal pain. He was diagnosed with Sickle cell crisis (long bone).

David is 6 years old Sickler who presented with severe bilateral thigh pains of 24 hours. There is history of passage of concentrated urine and fever prior to onset of the pains. Pain has been severe enough to prevent him from sleeping. There is history exposure to mosquito bite as well. No abdominal distension but there is abdominal pain. A young boy walking in with limping, jaundiced but not pale, typical sickle cell facie. Tenderness over the midthighs bilaterally. Diagnosis of Sickle Cell Crisis (long bones) was made. Patient was on admission for 7 days during which he was managed and closely monitored with some pain killers, injection antimalarials, injection antibiotics, transfused until stable. Patient was discharged, pain stopped as well as fever. No more abdominal pain. The family remains grateful for the medical support.

The patient is experiencing a vaso-occlusive sickle cell crisis affecting the long bones, resulting in significant pain and reduced mobility. With prompt treatment including adequate hydration, pain management, oxygen support when indicated, and close monitoring, recovery is expected. Ongoing follow-up is important to prevent recurrence and complications. T he overall prognosis for patients experiencing sickle cell long bone crises is significantly improved by modern disease-modifying therapies like hydroxyurea and crizanlizumab, though recurrent episodes carry a high risk of causing permanent skeletal damage and progressive joint disability over a lifetime.